U.S. markets open in 17 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.66-1.56 (-4.56%)
At close: 04:00PM EST
32.66 0.00 (0.00%)
After hours: 04:36PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close34.22
Bid27.00 x 1000
Ask40.43 x 900
Day's Range32.02 - 34.04
52 Week Range32.02 - 62.16
Avg. Volume443,401
Market Cap1.774B
Beta (5Y Monthly)1.52
PE Ratio (TTM)1.31
EPS (TTM)24.95
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agios Pharmaceuticals, Inc.
    Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Zacks

    Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Agios Appoints Richa Poddar as Chief Commercial Officer

    Darrin Miles to Depart Agios to Pursue a Chief Executive Officer OpportunityCAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021. Ms. Poddar will replace Darrin Miles, who currently serves as the company’s chief commercial officer and has been with Agios since

  • GlobeNewswire

    Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition

    – Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis – – New Data from Two Investigator Sponsored Studies of Mitapivat in Sickle Cell Disease Continue to Support Advancement to Pivotal Development – – First Data from the Phase 1 Healthy Volunteer Study of AG-946 Show Dose-dependent Changes in ATP and 2,3-DPG – – Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET – CAMBRIDG